Psychiatric Treatment Considerations With Direct Acting Antivirals in Hepatitis C

Sanjeev Sockalingam; Alice Tseng; Pierre Giguere; David Wong


BMC Gastroenterol. 2013;13(86) 

In This Article


In summary, this review summarizes the emerging body of evidence in this area but also acknowledges the remaining gaps in the literature. Studies utilizing more detailed psychiatric assessment tools during HCV treatment with DAAs are needed to increase our understanding of DAA related psychiatric complications. Additional drug interaction studies between DAAs and commonly used psychotropic agents are urgently needed. The results of these studies will be essential to guiding clinicians presented with challenges in interpreting DDI risks related to psychiatric care in the era of HCV triple therapy, in order to optimize HCV treatment outcomes and as well as management of psychiatric symptomatology.